Published by fairfieldmarketresearch
Posted on October 7, 2021
According to the National Cancer Institute, cancer survival rates over a five-year period in the US have demonstrated a marked improvement to 70% in 2020 – mainly due to improved healthcare, public policy, and novel pharmaceutical therapies. Oncology therapy comprised approx. a fifth of worldwide branded pharmaceutical sales and the oncology drugs market has consistently demonstrated double-digit growth for some time now.
Get a Sample Copy of Oncology Drugs Market @
https://www.fairfieldmarketresearch.com/report/oncology-drugs-market/request-sample
Companies Concentrating Their Efforts on Five Oncology Indications For Bulk Revenue
Although there are 20 different indications in oncology, the vast majority of revenue is derived from a quarter of those. In 2020, multiple myeloma, prostate cancer, non-small cell lung cancer and non-Hodgkin’s lymphoma (NHL) consists of more than half the oncology drugs market. Most drugs treat various types of cancers with three being anti-PD antibodies. A few other common cancers include skin, pancreatic, thyroid, renal, soft tissue, and brain cancer with breast, lung, and colorectal cancer accounting for more than 50% of all diagnosis in women.
Supply Chains Enable Transformation in Autologous Therapy in Oncology Drugs Market
RNA therapy, stem cell therapy, viral vectors, and cell therapy have been the buzzwords in the oncology drugs market with gene therapies leading to evermore complex supply chain and manufacturing processes – particularly for autologous therapies. Yescarta and Kymriah – two CAR-T cell therapies were approved for treating and diffuse large B-cell lymphoma and acute lymphocytic leukaemia respectively. The treatment and diagnostics regimen has progressed rapidly through precision medicine with approx. 160 oncology biomarkers authorized in 2019 and almost all of them against molecular targets. 4/5th of novel clinical assets are for marketed targets with four or more clinical competitors leading to quicker initial launches, shorter development cycles, and competitor therapies.
Maximum Activity Witnessed in Oncology With Thrice Development Spend of Other Sectors
Innovation in the oncology sector has boomed with the highest number of novel FDA approvals in this dynamic field. The estimated clinical development spend is thrice that of any other therapy area in phase III trials in the US. Oncology is responsible for roughly 2/5th of total expenditure and a third of total pipeline approvals in the US. In addition, it is one of the most expensive therapeutic areas in the pharmaceutical industry providing immense opportunities for companies in the oncology drugs market.
Do You Have Any Query Or Specific Requirement? Request for Custom Research:
https://www.fairfieldmarketresearch.com/report/oncology-drugs-market/request-customization
Dominance of Ten Companies in Oncology Drugs Market Unlikely to Erode Anytime Soon
The ten largest pharmaceutical companies have already declared oncology as a primary focus area of their R&D initiatives. There has been a flurry of M&A activity and strategic collaborations revolving around oncology drugs recently. In 2019, American giant Pfizer acquired Array BioPharma and Genmab and AbbVie entered into a strategic partnership to develop bispecific antibodies. The oncology drugs market is characterized by its oligopolistic nature with the top ten companies capturing 3/4th of the market value. The biggest companies are F. Hoffmann-La Roche AG (Roche), Celgene, Bristol-Myers Squibb, Johnson & Johnson, Pfizer, AstraZeneca, Merck & Co., Novartis, AbbVie, and Astellas Pharma. In 2020, Roche alone held a quarter of the global oncology drugs market but this share should decline by 2026 as its key products lose their popularity amongst patients.
Browse Our Latest Trending Reports:
About Us
Fairfield Market Research is a UK-based market research provider. Fairfield offers a wide spectrum of services, ranging from customized reports to consulting solutions. With a strong European footprint, Fairfield operates globally and helps businesses navigate through business cycles, with quick responses and multi-pronged approaches. The company values an eye for insightful take on global matters, ably backed by a team of exceptionally experienced researchers. With a strong repository of syndicated market research reports that are continuously published & updated to ensure the ever-changing needs of customers are met with absolute promptness.
Contact
Fairfield Market Research
London, UK
UK +44 (0)20 30025888
USA +1 (844) 3829746 (Toll-free)
Web: https://www.fairfieldmarketresearch.com/
Email: sales@fairfieldmarketresearch.com
Follow Us: LinkedIn
According to the National Cancer Institute, cancer survival rates over a five-year period in the US have demonstrated a marked improvement to 70% in 2020 – mainly due to improved healthcare, public policy, and novel pharmaceutical therapies. Oncology therapy comprised approx. a fifth of worldwide branded pharmaceutical sales and the oncology drugs market has consistently demonstrated double-digit growth for some time now.
Get a Sample Copy of Oncology Drugs Market @
https://www.fairfieldmarketresearch.com/report/oncology-drugs-market/request-sample
Companies Concentrating Their Efforts on Five Oncology Indications For Bulk Revenue
Although there are 20 different indications in oncology, the vast majority of revenue is derived from a quarter of those. In 2020, multiple myeloma, prostate cancer, non-small cell lung cancer and non-Hodgkin’s lymphoma (NHL) consists of more than half the oncology drugs market. Most drugs treat various types of cancers with three being anti-PD antibodies. A few other common cancers include skin, pancreatic, thyroid, renal, soft tissue, and brain cancer with breast, lung, and colorectal cancer accounting for more than 50% of all diagnosis in women.
Supply Chains Enable Transformation in Autologous Therapy in Oncology Drugs Market
RNA therapy, stem cell therapy, viral vectors, and cell therapy have been the buzzwords in the oncology drugs market with gene therapies leading to evermore complex supply chain and manufacturing processes – particularly for autologous therapies. Yescarta and Kymriah – two CAR-T cell therapies were approved for treating and diffuse large B-cell lymphoma and acute lymphocytic leukaemia respectively. The treatment and diagnostics regimen has progressed rapidly through precision medicine with approx. 160 oncology biomarkers authorized in 2019 and almost all of them against molecular targets. 4/5th of novel clinical assets are for marketed targets with four or more clinical competitors leading to quicker initial launches, shorter development cycles, and competitor therapies.
Maximum Activity Witnessed in Oncology With Thrice Development Spend of Other Sectors
Innovation in the oncology sector has boomed with the highest number of novel FDA approvals in this dynamic field. The estimated clinical development spend is thrice that of any other therapy area in phase III trials in the US. Oncology is responsible for roughly 2/5th of total expenditure and a third of total pipeline approvals in the US. In addition, it is one of the most expensive therapeutic areas in the pharmaceutical industry providing immense opportunities for companies in the oncology drugs market.
Do You Have Any Query Or Specific Requirement? Request for Custom Research:
https://www.fairfieldmarketresearch.com/report/oncology-drugs-market/request-customization
Dominance of Ten Companies in Oncology Drugs Market Unlikely to Erode Anytime Soon
The ten largest pharmaceutical companies have already declared oncology as a primary focus area of their R&D initiatives. There has been a flurry of M&A activity and strategic collaborations revolving around oncology drugs recently. In 2019, American giant Pfizer acquired Array BioPharma and Genmab and AbbVie entered into a strategic partnership to develop bispecific antibodies. The oncology drugs market is characterized by its oligopolistic nature with the top ten companies capturing 3/4th of the market value. The biggest companies are F. Hoffmann-La Roche AG (Roche), Celgene, Bristol-Myers Squibb, Johnson & Johnson, Pfizer, AstraZeneca, Merck & Co., Novartis, AbbVie, and Astellas Pharma. In 2020, Roche alone held a quarter of the global oncology drugs market but this share should decline by 2026 as its key products lose their popularity amongst patients.
Browse Our Latest Trending Reports:
About Us
Fairfield Market Research is a UK-based market research provider. Fairfield offers a wide spectrum of services, ranging from customized reports to consulting solutions. With a strong European footprint, Fairfield operates globally and helps businesses navigate through business cycles, with quick responses and multi-pronged approaches. The company values an eye for insightful take on global matters, ably backed by a team of exceptionally experienced researchers. With a strong repository of syndicated market research reports that are continuously published & updated to ensure the ever-changing needs of customers are met with absolute promptness.
Contact
Fairfield Market Research
London, UK
UK +44 (0)20 30025888
USA +1 (844) 3829746 (Toll-free)
Web: https://www.fairfieldmarketresearch.com/
Email: sales@fairfieldmarketresearch.com
Follow Us: LinkedIn
Explore more articles in the Research Reports category
